A Phase 3b trial published May 12 in Nature Medicine showed that switching from injectable semaglutide or tirzepatide to once-daily oral orforglipron held 75-79% of the weight loss over 52 weeks. Placebo groups kept only 37-49%. This is the first hard data on what happens when you swap the weekly shot for the daily pill — and it directly answers the question millions of patients are asking right now: can I keep the weight off without staying on injections forever?
Research-context information only. This article reports trial data and what it means for buyers. It is not medical advice. Talk to a licensed physician before changing any prescription protocol.
The short version: yes, mostly — if you switch to a maxed-out dose of orforglipron and accept some weight regain.
What the ATTAIN-MAINTAIN Trial Showed
ATTAIN-MAINTAIN ran for 52 weeks across 376 participants who had already completed the SURMOUNT-5 weight-loss trial on either tirzepatide (cohort 1, N=205) or semaglutide (cohort 2, N=171). Participants were randomized 3:2 to either daily orforglipron at maximum tolerated dose (24 mg or 36 mg) or matching placebo, alongside diet and exercise counseling.
Here are the maintenance numbers, which are the only ones that matter:
| Original Injectable | Switched To | Weight Loss Maintained | Avg. Weight Regain |
|---|---|---|---|
| Tirzepatide | Orforglipron 24-36 mg | 74.7% | 5 kg (11 lb) |
| Tirzepatide | Placebo | 49.2% | ~10-12 kg |
| Semaglutide | Orforglipron 24-36 mg | 79.3% | 1 kg (2.2 lb) |
| Semaglutide | Placebo | 37.6% | ~7-9 kg |
The semaglutide-to-pill cohort barely budged — 1 kg over a year is rounding error in obesity medicine. The tirzepatide cohort regained more, which makes sense: tirzepatide is the more potent injectable, so dropping to a less potent oral maintenance drug leaves a bigger efficacy gap to fill.
Cardiometabolic benefits — improved cholesterol, blood pressure, A1c, and waist circumference — also held across both cohorts on orforglipron. Side effects were the standard GLP-1 GI complaints (nausea, mild diarrhea), mostly mild-to-moderate.
What This Means for Anyone on Injectable GLP-1s Right Now
This is the practical question. Three scenarios cover most readers:
Scenario 1: You hit your target weight on semaglutide or tirzepatide and want off the shots
Pre-trial, the standard answer was "stay on a maintenance dose forever or accept significant regain." ATTAIN-MAINTAIN gives a third option: switch to oral orforglipron and hold the majority of your loss with a daily pill, no needles.
Caveats:
- The trial used maximum tolerated dose (24 or 36 mg orforglipron daily). Lower doses were not tested for maintenance — assume the maintenance effect drops with the dose.
- The semaglutide cohort held more weight than the tirzepatide cohort. If you are coming off tirzepatide, plan for ~5 kg of regain over a year.
- The drug is FDA-approved for obesity but Lilly has not filed a specific maintenance label yet. This is off-label use for now.
Scenario 2: You are still actively losing weight on injectables
Do not switch yet. Orforglipron at 12% peak weight loss is the weaker drug; switching mid-loss caps your potential. Finish the active phase on injectables, then evaluate maintenance.
Scenario 3: You stopped injections months ago and have already regained weight
Restart-and-switch is plausible: rebuild loss on injectable semaglutide or tirzepatide, then transition to orforglipron once stable. Or restart compounded GLP-1s at lower maintenance doses if pill access or cost is the issue.
Scenario 4: You cannot get insurance to cover orforglipron
Self-pay is $149-299/month through Lilly's Self-Pay Journey program. Cheaper alternatives:
- Continued compounded semaglutide at a low maintenance dose (0.5-1 mg weekly) often runs $100-150/month and keeps you on the drug that has actual maintenance evidence behind it
- Continued compounded tirzepatide at maintenance dose (2.5-5 mg weekly) runs $150-250/month
- Oral semaglutide pills exist but the original ATTAIN-MAINTAIN trial did not test them for maintenance — assume they underperform the injectable version (they always have on weight loss too)
